Ignite Creation Date:
2025-12-24 @ 5:14 PM
Ignite Modification Date:
2026-01-01 @ 6:07 PM
Study NCT ID:
NCT01339650
Status:
COMPLETED
Last Update Posted:
2018-01-02
First Post:
2011-04-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor:
AbbVie (prior sponsor, Abbott)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-05-06
Start Date Type:
ACTUAL
Primary Completion Date:
2017-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-11-30
Completion Date Type:
ACTUAL
First Submit Date:
2011-04-04
First Submit QC Date:
None
Study First Post Date:
2011-04-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-12-28
Last Update Post Date:
2018-01-02
Last Update Post Date Type:
ACTUAL